UBS Group’s Spero Therapeutics SPRO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$23.8K Buy
8,194
+5,368
+190% +$15.6K ﹤0.01% 7015
2025
Q1
$2.04K Buy
2,826
+2,685
+1,904% +$1.93K ﹤0.01% 8092
2024
Q4
$145 Sell
141
-17,388
-99% -$17.9K ﹤0.01% 8357
2024
Q3
$23.5K Buy
17,529
+17,198
+5,196% +$23K ﹤0.01% 6069
2024
Q2
$430 Sell
331
-5,397
-94% -$7.01K ﹤0.01% 7759
2024
Q1
$9.85K Buy
5,728
+5,399
+1,641% +$9.29K ﹤0.01% 6091
2023
Q4
$484 Sell
329
-26,806
-99% -$39.4K ﹤0.01% 7423
2023
Q3
$32.8K Buy
27,135
+64
+0.2% +$77 ﹤0.01% 5419
2023
Q2
$39.3K Sell
27,071
-14,452
-35% -$21K ﹤0.01% 5530
2023
Q1
$60.2K Sell
41,523
-4,159
-9% -$6.03K ﹤0.01% 5233
2022
Q4
$79K Buy
45,682
+22,774
+99% +$39.4K ﹤0.01% 5189
2022
Q3
$46K Buy
22,908
+22,153
+2,934% +$44.5K ﹤0.01% 5363
2022
Q2
$1K Hold
755
﹤0.01% 8909
2022
Q1
$7K Sell
755
-32,327
-98% -$300K ﹤0.01% 7785
2021
Q4
$529K Buy
33,082
+4,260
+15% +$68.1K ﹤0.01% 3937
2021
Q3
$530K Buy
28,822
+26,929
+1,423% +$495K ﹤0.01% 3699
2021
Q2
$27K Sell
1,893
-29,134
-94% -$416K ﹤0.01% 5961
2021
Q1
$456K Buy
31,027
+16,680
+116% +$245K ﹤0.01% 4002
2020
Q4
$278K Buy
14,347
+13,847
+2,769% +$268K ﹤0.01% 4068
2020
Q3
$6K Sell
500
-5,452
-92% -$65.4K ﹤0.01% 6353
2020
Q2
$80K Sell
5,952
-3,041
-34% -$40.9K ﹤0.01% 4657
2020
Q1
$73K Sell
8,993
-5,274
-37% -$42.8K ﹤0.01% 4667
2019
Q4
$137K Buy
14,267
+3,216
+29% +$30.9K ﹤0.01% 4817
2019
Q3
$117K Sell
11,051
-751
-6% -$7.95K ﹤0.01% 4758
2019
Q2
$136K Buy
+11,802
New +$136K ﹤0.01% 4345
2019
Q1
Sell
-3,200
Closed -$20K 7101
2018
Q4
$20K Buy
3,200
+841
+36% +$5.26K ﹤0.01% 5873
2018
Q3
$25K Buy
2,359
+1,414
+150% +$15K ﹤0.01% 5762
2018
Q2
$13K Buy
945
+449
+91% +$6.18K ﹤0.01% 6078
2018
Q1
$7K Buy
496
+368
+288% +$5.19K ﹤0.01% 6196
2017
Q4
$1K Buy
+128
New +$1K ﹤0.01% 6744